Datasheet for ABIN748518

anti-LAG3 antibody (AA 210-260) (PE)

1 Publication

Go to Product page

Overview

Quantity:	100 µL
Target:	LAG3
Binding Specificity:	AA 210-260
Reactivity:	Human, Mouse, Rat
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This LAG3 antibody is conjugated to PE
Application:	Western Blotting (WB)

Product Details

Immunogen:	KLH conjugated synthetic peptide derived from human Lymphocyte Activation Gene 3
Isotype:	IgG
Cross-Reactivity:	Human, Mouse
Predicted Reactivity:	Rat,Cow,Pig,Horse,Rabbit
Purification:	Purified by Protein A.

Target Details

Target:	LAG3
Alternative Name:	Lymphocyte Activation Gene 3 (LAG3 Products)
Background:	Synonyms: CD223, Lymphocyte activation gene 3 protein, LAG-3, Lag3

Target Details

	Background: Lymphocyte-activation protein 3 (LAG-3), also known as CD223, belongs to the immunoglobulin superfamily and contains 4 extracellular Ig-like domains. LAG-3 binds to HLA class-II antigens and is involved in lymphocyte activation. It is found on the cell surface of activated NK and T-lymphocytes. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG-3 to CD4.
Gene ID:	297596
UniProt:	Q5BK54
Pathways:	Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints

Application Details

Application Notes:	FCM(1:20-100)
Restrictions:	For Research Use only

Handling

Format:	Liquid
Concentration:	1 μg/μL
Buffer:	Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
Preservative:	Sodium azide
Precaution of Use:	This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
Storage:	-20 °C
Storage Comment:	Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Expiry Date:	12 months

Publications

Product cited in:	Parodi, Battaglia, Kalli, Ferrera, Conteduca, Tardito, Stringara, Ivaldi, Negrini, Borgonovo, Simonato, Traverso, Carmignani, Fenoglio, Filaci: "CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes." in: **Cancer immunology, immunotherapy : CII**, Vol. 62, Issue 5, pp. 851-62, (2013) (PubMed).

